California Bill Directs State to Partner With Manufacturers on Lower-Cost GLP-1s Under CalRx
California Senate Bill 1089 would direct the state to seek partnerships with drug manufacturers to produce lower-cost GLP-1 medications through its CalRx program, which currently distributes insulin, albuterol, and naloxone. The bill, authored by Sen. Laura Richardson, originally sought to mandate GLP-1 coverage by CalPERS but was revised after the insurer estimated premiums would increase $28 per member monthly. The legislation follows California's elimination of Medi-Cal coverage for GLP-1s prescribed for obesity treatment due to budget pressures, though coverage remains for diabetes indications. GLP-1 prescriptions for weight loss in California jumped from 20,000 to 700,000 between 2018 and 2023, with Medi-Cal spending $416.8 million on weight-loss GLP-1s in 2023 before cutting the benefit.
California's Medicaid program eliminated obesity-indication GLP-1 coverage in response to spending that reached $416.8 million in 2023, and this legislation reflects ongoing state efforts to balance access with fiscal sustainability through manufacturing partnerships rather than coverage mandates.
Pharmacy · Finance
You might also like